A significant obstacle still faced in oncology is damage to healthy cells inflicted during treatment, which robs patients of their quality of life while battling cancer. Targeted radionuclide therapy (TRT) is a type of radiomolecular precision oncology that addresses this issue by deploying cancer-killing radiation directly to tumour cells, with little damage to healthy, surrounding tissue. Richard Baum, President of the International Centers for Precision Oncology (ICPO) Academy, explains more.
Despite great therapeutic advances, cancer remains a leading cause of death worldwide. A major limitation in the treatment for most cancers is the inability of therapies to effectively target cancer cells without damaging normal ones. Precision diagnosis and treatment providing a personalised approach is the new focus for patients with cancer. An exciting, novel approach, targeted radionuclide therapy (TRT) has emerged as a novel avenue to specifically target cancer cells. TRT is very different from traditional radiation therapy, which uses external beam radiation to destroy cancer cells. TRT, a form of radiomolecular precision oncology, uses a sophisticated targeting approach that keeps patient wellbeing at the forefront of therapy, from diagnosis to treatment.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
A new approach to targeting cancer
At the heart of TRT is a new class of drugs called radiopharmaceuticals, which deliver radiation directly to cancer cells. Radiopharmaceuticals consist of a specific cancer-targeting molecule (eg, a peptide or antibody) combined with a radioisotope, which kills the cells. The radiopharmaceutical (the ‘key’) is injected intravenously and circulates through the bloodstream until it binds to the tumour‑specific receptor or enzyme (the ‘lock’). Once attached to the cancer cells (see Figure 1), the radioisotope emits ionising radiation that damages DNA, resulting in cancer cell death and halted tumour growth, with little damage to the normal surrounding tissues. Given this highly precise localisation, TRT is rapidly emerging as a high‑potential radiation oncology treatment for patients with cancer who have limited treatment options.
Transforming cancer diagnosis with precision localisation
In the case of patients with metastatic cancer, accurate and sensitive imaging enables the early detection of cancers that would otherwise spread rapidly and silently, presenting late with advanced disease. Radioisotopes in conjunction with highly sensitive molecular imaging technologies such as PET (positron-emission tomography) or SPET (single‑photon emission tomography) help to visualise tiny deposits of cancer cells in affected organs that are otherwise too small to be detected by conventional imaging like computerised tomography (CT) or magnetic resonance imaging (MRI).
If you can see it, you can treat it
An attractive feature of TRT is that the targeting molecule can typically be used interchangeably for diagnosis and therapy, requiring only a change of the medical radioisotope. This affords doctors an early impression of whether the treatment will work. Usually, a radioisotope with a short half-life is used for diagnosis, while those with longer half‑lives are used for therapy. Radiation is emitted either as alpha or beta particles, or gamma rays. Alpha particles (high charge, low penetration power) and beta particles (lower charge, higher penetration power) are typically used for treatment and positron emission/gamma rays (no charge, high penetration) are used for diagnosis. TRT therefore enables the concept of ‘theranostics’ (therapy and diagnostics), which is guided by the founding principle: if you can see it, you can treat it.
The potential of radiomolecular medicine
As a rising star in precision oncology, TRT is redefining the concept of radiomolecular (previously named “nuclear”) medicine, enabling it to reach its full potential by improving patient outcomes while supporting quality of life. In cancer, where treatment is often limited by advanced disease, TRT presents an attractive opportunity to deliver targeted and precise treatment to patients who otherwise have very limited treatment options. This treatment method is already being used in indications such as neuroendocrine tumours of gastroenteric, pancreatic (GEP-NETs) or lung origin.1 Due to their asymptomatic nature, these types of neoplasms often go undetected for prolonged periods of time until they have metastasised, making surgical cure impossible. Although GEP‑NETs are classified as rare cancers,2 the number of people living with this disease is quite high, with numbers rising year-on-year.3 For these patients, TRT stands as a new approach for effectively delivering medication addressing an otherwise unmet need.
Figure 1: The key-and-lock principle (reference 10)
The rarest drug on Earth: supply and demand of radioisotopes
To fully harness the power of targeted radionuclide therapy, the production and supply of medical radioisotopes is critical. This is particularly true for rare radioisotopes such as actinium-225, sometimes referred to as “the rarest drug on earth”. Although limited amounts of the radioisotope are readily available, actinium’s promise is exponential. Companies are working hard to achieve the means and expertise to produce it effectively and efficiently. Rare or not, all medical radioisotopes must not only be produced and supplied quickly to meet a rising global patient population, but they must also adhere to strict quality control measures. Obtaining highly pure, contaminant-free radioisotopes is imperative to provide patients with top quality diagnoses and treatments. From research, production and supply, and all the way to drug development, TRT is receiving heightened attention.
Late-stage clinical progress and successes
TRT has been investigated in various clinical trials that are making waves in the industry and have yielded very promising results. In 2013, radium-223-dichloride (Xofigo) was approved as the first alpha emitter to treat painful bone metastases of prostate cancer. Approvals for other radiopharmaceuticals followed in recent years. In 2018, for instance, lutetium-177-dotatate (Lutathera) was approved for the treatment of various neuroendocrine tumours (NETs) affecting mainly the digestive tract. Further candidates are in clinical development: Germany-based ITM Isotope Technologies Munich SE, for example, is conducting two pivotal Phase III clinical trials, COMPETE4 and COMPOSE,5 exploring the TRT approach with n.c.a. lutetium-177-edotreotide in patients with GEP‑NETs. Both trials build on promising Phase II data that demonstrated improved progression‑free survival, a low uptake by normal organs and a high tumour‑to-kidney ratio.6 Additionally, Novartis has published positive results from a Phase III trial called VISION, which studied TRT with lutetium-177‑PSMA-617 in patients with advanced, metastatic prostate cancer. It is expected that this treatment will become available for prostate cancer patients this year. Due to its emerging success, entire conferences are now dedicated to TRT, including the Theranostics World Congress7 and the International Centers for Precision Oncology (ICPO) Forum, which bring together international experts and patient advocacy representatives to discuss novel developments in this rapidly developing field.
A new era of personalised medicine
With its ability to selectively destroy cancer cells and even bulky tumours while giving patients a high quality of life during treatment, TRT poses an exciting new avenue in the field of personalised medicine. It holds the potential to unlock multiple treatment channels utilising an array of targeting methods and medical radioisotopes. For example, new radiopharmaceuticals are being developed to target the fibroblast activation protein (FAP), which is highly expressed and detectable in the majority of epithelial cancers, including over 90 percent of breast, lung, colorectal and pancreatic carcinomas.8 Following on from beta-radioisotopes, targeted alpha therapy provides highly localised, powerful radiation which is particularly lethal to cancer cells. This versatility has led to companies being founded specifically around TRT.9 Targeted radionuclide therapy has ushered in a new era of precision oncology and personalised medicine. This multifaceted therapeutic modality is on an accelerated path forwards and is providing new therapeutic approaches to patients with cancer who have limited treatment options.
PROF. DR. MED. Richard Baum is President of the International Centers for Precision Oncology (ICPO) Academy, Board member of the ICPO, and Consultant of the Advanced Center for Radio-molecular Precision Oncology at Curanosticum Wiesbaden-Frankfurt. He performed the first radioimmunotherapy and peptide receptor therapy in Germany and the first 177Lu-based prostate-specific membrane antigen radioligand therapy globally. Richard has treated over 2,000 patients with more than 7,000 PRRT applications. He has received accolades including the Saul Hertz Award, a prestigious nuclear medicine lifetime award. An avid supporter of theranostics with professorships around the world, Richard contributes greatly, clinically and academically, to nuclear medicine.
References
Malcolm J, Falzone N, Lee B, Vallis K. Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response. Cancers [Internet]. MDPI AG; 2019 Feb 25;11(2):268. Available from: http://dx.doi.org/10.3390/cancers11020268
2. Oronsky B, Ma P, Morgensztern D, Carter C. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia [Internet]. 2017;19(12):991-1002. Available from: https://www.sciencedirect.com/science/article/pii/S1476558617303470
Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncology [Internet]. 2017;3(10):1335. Available from: https://pubmed.ncbi.nlm.nih.gov/28448665/
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients – Full Text View – ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2022 [cited 19 January 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT03049189
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) – COMPOSE – Full Text View – ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2022 [cited 19 January 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT04919226
Baum R, Kluge A, Kulkarni H, et al. [177Lu-DOTA]0-D-Phe1-Tyr3-Octreotide (177Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study. Theranostics. 2016;6(4):501-510. doi: 10.7150/thno.13702
Theranostics World Congress [Internet]. Twc-2022.org. 2022 [cited 19 January 2022]. Available from: https://www.twc-2022.org/
Altmann A, Haberkorn U, Siveke J. The Latest Developments in Imaging of Fibroblast Activation Protein. Journal of Nuclear Medicine [Internet]. 2020;62(2):160-167. Available from: https://jnm.snmjournals.org/content/62/2/160
Radiopharmaceutical Market Shows Huge Demand and Future Scope Including Top Players 2031 | Medgadget [Internet]. Medgadget.com. 2021 [cited 8 December 2021]. Available from: https://www.medgadget.com/2021/10/radiopharmaceutical-market-shows-huge-demand-and-future-scope-including-top-players-2031.html 10. ITM – Targeted
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.